Evidence map›Paper›PMID 36891156›Full record

ArticleFrontiers in cellular and infection microbiology2023

Plerixafor and resatorvid inhibit hepatitis B virus

Jinyuan Cai, Yuwen Li, Pingping Hu, Ruirui Xu, Hui Yuan, Wen Zhang, Tiantong Feng, Rui Liu, Wenting Li, Chuanlong Zhu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. [Inhibitory effect of small-molecule compound AM679 targeting elongation-factor binding protein 2 on hepatitis B virus in vitro].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Jinyuan Cai1Department of Infectious Disease, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yuwen LiDepartment of Pediatrics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Pingping HuDepartment of Infectious Disease, Zhongda Hospital, Southeast University, Nanjing, China.
Ruirui XuDepartment of Infectious Disease, Zhongda Hospital, Southeast University, Nanjing, China.
Hui YuanDepartment of Infectious Disease, Zhongda Hospital, Southeast University, Nanjing, China.
Wen ZhangDepartment of Infectious Disease, Zhongda Hospital, Southeast University, Nanjing, China.
Tiantong FengDepartment of Infectious Disease, Zhongda Hospital, Southeast University, Nanjing, China.
Rui LiuDepartment of Infectious and Tropical Diseases, The Second Affiliated Hospital of Hainan Medical University, Hainan, China.
Wenting LiDepartment of Infectious and Tropical Diseases, The Second Affiliated Hospital of Hainan Medical University, Hainan, China.
Chuanlong Zhu1Department of Infectious Disease, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Zhongda Hospital Southeast University · CNHainan Medical University · CNJiangsu Province Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: An increase in the demand for a functional cure has accelerated research on new methods of therapy for chronic hepatitis B, which is mainly focused on restoring antiviral immunity for controlling viral infections. Previously, we had described elongation factor Tu GTP-binding domain containing 2 (EFTUD2) as an innate immune regulator and suggested that it might be an antiviral target. Methods: In this study, we generated the Epro-LUC-HepG2 cell model for screening compounds that target EFTUD2. Plerixafor and resatorvid were screened from 261 immunity and inflammation-related compounds due to their ability to highly upregulate EFTUD2. The effects of plerixafor and resatorvid on hepatitis B virus (HBV) were examined in HepAD38 cells and HBV-infected HepG2-NTCP cells. Results: The dual-luciferase reporter assays showed that the EFTUD2 promoter hEFTUD2pro-0.5 kb had the strongest activity. In Epro-LUC-HepG2 cells, plerixafor and resatorvid significantly upregulated the activity of the EFTUD2 promoter and the expression of the gene and protein. In HepAD38 cells and HBV-infected HepG2-NTCP cells, treatment with plerixafor and resatorvid strongly inhibited HBsAg, HBV DNA, HBV RNAs, and cccDNA in a dose-dependent manner. Furthermore, the anti-HBV effect was enhanced when entecavir was administered along with either of the previous two compounds, and the effect could be blocked by knocking down EFTUD2. Conclusion: We established a convenient model for screening compounds that target EFTUD2 and further identified plerixafor and resatorvid as novel HBV inhibitors

Indexed as

Hepatitis BHeterocyclic CompoundsAntiviral AgentsDNA, ViralGuanosine TriphosphateHematopoietic Stem Cell MobilizationHepatitis B virusHep G2 CellsHumansPeptide Elongation FactorsPeptide Elongation Factor TuRibonucleoprotein, U5 Small NuclearSulfonamidesVirus ReplicationAntiviral AgentsDNA, ViralEFTUD2 protein, humanethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylateGuanosine TriphosphateHeterocyclic CompoundsPeptide Elongation FactorsPeptide Elongation Factor TuRibonucleoprotein, U5 Small NuclearSulfonamidesEFTUD2hepatitis B virusplerixaforresatorvidsmall-molecule agents

Identifiers

PMID36891156
PMCPMC9986551
OpenAlexW4321375683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.